N -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment-Reference-Cited by-同舟云学术

N -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment

Published:2020-03-24 Issue:4 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mthiyane Thuli¹,Millard James²³⁴,Adamson John⁴,Balakrishna Yusentha⁵,Connolly Cathy⁵,Owen Andrew⁶,Rustomjee Roxana¹,Dheda Keertan⁷,McIlleron Helen⁸,Pym Alexander S.¹⁴

Affiliation:

1. South African Medical Research Council, Durban, South Africa

2. Wellcome Trust Liverpool Glasgow Centre for Global Health Research, Liverpool, United Kingdom

3. Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom

4. Africa Health Research Institute, Durban, South Africa

5. South African Medical Research Council, Biostatistics Department, Durban, South Africa

6. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom

7. Lung Infection and Immunity Unit, Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa

8. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

Abstract

The distribution of N -acetyltransferase 2 gene ( NAT2 ) polymorphisms varies considerably among different ethnic groups. Information on NAT2 single-nucleotide polymorphisms in the South African population is limited. We investigated NAT2 polymorphisms and their effect on isoniazid pharmacokinetics (PK) in Zulu black HIV-infected South Africans in Durban, South Africa. HIV-infected participants with culture-confirmed pulmonary tuberculosis (TB) were enrolled from two unrelated studies.

Funder

United States Agency for International Development

Agence Nationale de la Recherche

European and Developing Countries Clinical Trials Partnership

Wellcome Trust

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02376-19

Reference67 articles.

1. World Health Organization. 2019. Global tuberculosis report. World Health Organization, Geneva, Switzerland.

2. Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana

3. Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

4. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans;Lauterburg BH;J Pharmacol Exp Ther,1985

5. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Case for Pre-Emptive Pharmacogenetic Screening in South Africa;Journal of Personalized Medicine;2024-01-19

2. Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity;BMC Medical Genomics;2024-01-06

3. Isoniazid-induced liver injury risk level in different variants of N-acetyltransferase 2 (NAT2) polymorphisms: A literature review;Pharmacia;2023-10-04

4. Severe efavirenz associated neurotoxicity: A retrospective cohort study;Southern African Journal of Infectious Diseases;2023-07-24

5. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients;Scientific Reports;2023-07-15